Kairos Pharma Ltd. (NYSE American: KAPA) announced that its CEO and Chairman Dr. John Yu will present at the 16th Annual LD Micro Invitational on May 18, 2026, at 1:00 p.m. PDT at the Luxe Sunset Boulevard Hotel in Los Angeles. The presentation will offer an update on the company's clinical program and partnering activities, as detailed in the press release.
Based in Los Angeles, California, Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company's lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.
Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. As of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
The LD Micro Invitational is a key event for emerging growth companies, providing a platform to connect with investors and industry experts. Dr. Yu's presentation will likely highlight recent data and strategic partnerships, offering insights into Kairos Pharma's progress in developing therapies that could transform cancer treatment. For more updates on the company, visit the Kairos Pharma newsroom.
This announcement underscores the importance of Kairos Pharma's work in tackling drug resistance, one of the biggest challenges in oncology. If successful, ENV-105 could provide new options for patients with hard-to-treat cancers, potentially improving outcomes and quality of life.